Liposome-targeted delivery for highly potent drugs

References

• Al-Ahmady ZS, Chaloin O, Kostarelos K. 2014. Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release. 196:332–343.
   PubMed Web of Science ®Google Scholar
• Al-Dosari MS, Gao X. 2009. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 11:671–681.
   PubMed Web of Science ®Google Scholar
• Apps MG, Choi EH, Wheate NJ. 2015. The state-of-play and future of platinum drugs. Endocr Relat Cancer. 22:R219–R233.
   PubMed Web of Science ®Google Scholar
• Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, et al. 2011. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. Bioconjug Chem. 22:429–435.
   PubMed Web of Science ®Google Scholar
• Baek SE, Lee KH, Park YS, Oh DK, Oh S, Kim KS, Kim DE. 2014. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release. 196:234–242.
   PubMed Web of Science ®Google Scholar
• Balazs DA, Godbey W. 2011. Liposomes for use in gene delivery. J Drug Deliv. 2011:326497.
   PubMedGoogle Scholar
• Bardania H, Shojaosadati SA, Kobarfard F, Dorkoosh F, Zadeh ME, Naraki M, Faizi M. 2016a. Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity. J Thromb Thrombolysis. [Epub ahead of print]. doi: 10.1007/s11239-016-1440-6
   PubMed Web of Science ®Google Scholar
• Bardania H, Shojaosadati SA, Kobarfard F, Dorkoosh F. 2016b. Optimization of RGD-modified nano-liposomes encapsulating eptifibatide. Iran J Biotechnol. 14:33–40.
   PubMed Web of Science ®Google Scholar
• Basavaraj S, Betageri GV. 2014. Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges. Acta Pharmaceutica Sinica B. 4:3–17.
   PubMed Web of Science ®Google Scholar
• Belogurov AA, Stepanov AV, Smirnov IV, Melamed D, Bacon A, Mamedov AE, et al. 2013. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 27:222–231.
   PubMed Web of Science ®Google Scholar
• Bi R, Shao W, Wang Q, Zhang N. 2008. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target. 16:639–648.
   PubMed Web of Science ®Google Scholar
• Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A. 1999. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Cancer Res. 5:687–693.
   PubMed Web of Science ®Google Scholar
• Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, Lu Y. 2009. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl. 48:6494–6498.
   PubMed Web of Science ®Google Scholar
• Chang DK, Li PC, Lu RM, Jane WN, Wu HC. 2013. Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. PLoS One. 8:e83239.
   PubMed Web of Science ®Google Scholar
• Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M. 2010. Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther. 17:512–522.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bathula SR, Li J, Huang L. 2010. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem. 285:22639–22650.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu JJ, Huang L. 2010. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther. 18:828–834.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Zhang X, Liu B, Huang L. 2010. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 18:1650–1656.
   PubMed Web of Science ®Google Scholar
• Cheng W, Allen T. 2010. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv. 7:461–478.
   PubMed Web of Science ®Google Scholar
• Chime SA, Onyishi IV. 2013. Lipid-based drug delivery systems (LDDS): recent advances and applications of lipids in drug delivery. Afr J Pharm Pharmacol. 7:3034–3059.
   Google Scholar
• Cryan SA. 2005. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7:E20–E41.
   PubMed Web of Science ®Google Scholar
• da Cruz MTG, Simões S, de Lima MCP. 2004. Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol. 187:65–75.
   PubMed Web of Science ®Google Scholar
• Daraee H, Eatemadi A, Abbasi E, Fekri Aval S, Kouhi M, Akbarzadeh A. 2016. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 44:381–391.
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. 2013. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 8:1509–1528.
   PubMed Web of Science ®Google Scholar
• Eldar-Boock A, Polyak D, Scomparin A, Satchi-Fainaro R. 2013. Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. Curr Opin Biotechnol. 24:682–689.
   PubMed Web of Science ®Google Scholar
• Eliaz RE, Szoka FC. 2001. Liposome-encapsulated doxorubicin targeted to CD44 a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61:2592–2601.
   PubMed Web of Science ®Google Scholar
• Eloy JO, Claro de Souza M, Petrilli R, Barcellos JP, Lee RJ, Marchetti JM. 2014. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 123:345–363.
   PubMed Web of Science ®Google Scholar
• Ewert KK, Kotamraju VR, Majzoub RN, Steffes VM, Wonder EA, Teesalu T, Ruoslahti E, Safinya CR. 2016. Synthesis of linear and cyclic peptide–PEG–lipids for stabilization and targeting of cationic liposome–DNA complexes. Bioorg Med Chem Lett. 26:1618–1623.
   PubMed Web of Science ®Google Scholar
• Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 84:7413–7417.
   PubMed Web of Science ®Google Scholar
• Feng C, Wang T, Tang R, Wang J, Long H, Gao X, Tang S. 2010. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int. 26:1185–1191.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid–PEG conjugates. Adv Drug Deliv Rev. 56:1177–1192.
   PubMed Web of Science ®Google Scholar
• Gagné JF, Désormeaux A, Perron S, Tremblay MJ, Bergeron MG. 2002. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta. 1558:198–210.
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. 2014. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 194:238–256.
   PubMed Web of Science ®Google Scholar
• Gandhi R, Khatri N, Baradia D, Vhora I, Misra A. 2015. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. Drug Deliv. 23:1152–1162.
   PubMed Web of Science ®Google Scholar
• Glasgow MD, Chougule MB. 2015. Recent developments in active tumor targeted multifunctional nanoparticles for combination chemotherapy in cancer treatment and imaging. J Biomed Nanotechnol. 11:1859–1898.
   PubMed Web of Science ®Google Scholar
• Goodall S, Jones ML, Mahler S. 2015. Monoclonal antibody‐targeted polymeric nanoparticles for cancer therapy–future prospects. J Chem Technol Biotechnol. 90:1169–1176.
   Web of Science ®Google Scholar
• Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. 2000. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 6:1949–1957.
   PubMed Web of Science ®Google Scholar
• Haller CA, Cui W, Wen J, Robson SC, Chaikof EL. 2006. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J Vasc Surg. 43:816–823.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Maitani Y. 2004. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release. 97:173–183.
   PubMed Web of Science ®Google Scholar
• He C, Tang Z, Tian H, Chen X. 2016. Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv Drug Deliv Rev. 98:64–76.
   PubMed Web of Science ®Google Scholar
• He Y, Zhang L, Song C. 2010. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomedicine. 5:697–705.
   PubMed Web of Science ®Google Scholar
• Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, et al. 2010. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm. 391:274–283.
   PubMed Web of Science ®Google Scholar
• Hua X, Zhou L, Liu P, He Y, Tan K, Chen Q, Gao Y, Gao Y. 2014. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. J Thromb Thrombolysis. 38:57–64.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu Y. 2011. In vivo delivery of RNAi with lipid-based nanoparticles. Ann Rev Biomed Eng. 13:507–530.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou F. 1992. Liposome and immunoliposome mediated delivery of proteins and peptides. In: Gregoriadis G, Florence AT, Poste G, Eds. Targeting of Drugs 3. New York: Springer, pp. 45–50.
   Google Scholar
• Hyndman L, Lemoine JL, Huang L, Porteous DJ, Boyd AC, Nan X. 2004. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release. 99:435–444.
   PubMed Web of Science ®Google Scholar
• Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, et al. 2002. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 99:130–137.
   PubMed Web of Science ®Google Scholar
• Ishii T, Asai T, Oyama D, Fukuta T, Yasuda N, Shimizu K, et al. 2012. Amelioration of cerebral ischemia–reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J Control Release. 160:81–87.
   PubMed Web of Science ®Google Scholar
• Ishiwatari H, Sato Y, Murase K, Yoneda A, Fujita R, Nishita H, et al. 2013. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut. 62:1328–1339.
   PubMed Web of Science ®Google Scholar
• Iwase Y, Maitani Y. 2010. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Mol Pharm. 8:330–337.
   Web of Science ®Google Scholar
• Jain AK, Chalasani KB, Khar RK, Ahmed FJ, Diwan PV. 2007. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target. 15:417–427.
   PubMed Web of Science ®Google Scholar
• Javadi M, Pitt WG, Tracy CM, Barrow JR, Willardson BM, Hartley JM, Tsosie NH. 2013. Ultrasonic gene and drug delivery using eLiposomes. J Control Release. 167:92–100.
   PubMed Web of Science ®Google Scholar
• Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, et al. 2014. Liposomes, modified with PTD HIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 35:7610–7621.
   PubMed Web of Science ®Google Scholar
• Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. 2003. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm. 29:1149–1153.
   PubMed Web of Science ®Google Scholar
• Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. 2001. A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol. 53:295–302.
   PubMed Web of Science ®Google Scholar
• Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K. 2002. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release. 82:183–187.
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. 2013. Delivery materials for siRNA therapeutics. Nat Mater. 12:967–977.
   PubMed Web of Science ®Google Scholar
• Kisel M, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, Kholodova EA, Zabarovskaya ZV. 2001. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 216:105–114.
   PubMed Web of Science ®Google Scholar
• Kohara N, Kitaoka F, Komuta K, Yamamoto M, Motojima K, Kanematsu T. 1995. Effective treatment of liver metastases from colon cancer with a combination of γ-interferon and cisplatin chemotherapy: report of a case. Surg Today. 25:357–360.
   PubMed Web of Science ®Google Scholar
• Kong F, Zhou F, Ge L, Liu X, Wang Y. 2012. Mannosylated liposomes for targeted gene delivery. Int J Nanomedicine. 7:1079–1089.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. 2006. Immunoliposomes for cancer therapy. Curr Opin Mol Ther. 8:39.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. 2012. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther. 13:50–60.
   PubMed Web of Science ®Google Scholar
• Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, Bendas G. 2010. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 389:10–17.
   PubMed Web of Science ®Google Scholar
• Lajavardi L, Camelo S, Agnely F, Luo W, Goldenberg B, Naud MC, et al. 2009. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release. 139:22–30.
   PubMed Web of Science ®Google Scholar
• Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z. 2014. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 35:3840–3850.
   PubMed Web of Science ®Google Scholar
• Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, et al. 2013. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials. 34:3366–3380.
   PubMed Web of Science ®Google Scholar
• Li X, Ding L, Xu Y, Wang Y, Ping Q. 2009. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm. 373:116–123.
   PubMed Web of Science ®Google Scholar
• Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J. 2010. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm. 8:250–259.
   PubMed Web of Science ®Google Scholar
• Liu YJ, Dou XQ, Wang F, Zhang J, Wang XL, Xu GL, et al. 2016. IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment. J Drug Target. [Epub ahead of print]. doi: http://dx.doi.org/10.1080/1061186X.2016.1258569
   Web of Science ®Google Scholar
• Lopez-Berestein G, Fidler IJ. 1989. Liposomes in the Therapy of Infectious Diseases and Cancer. New York: Alan R. Liss, pp. 245–262.
   Google Scholar
• Lu Y, Yang J, Sega E. 2006. Issues related to targeted delivery of proteins and peptides. AAPS J. 8:E466–E478.
   PubMed Web of Science ®Google Scholar
• Lv Q, Li LM, Han M, Tang XJ, Yao JN, Ying XY, Li FZ, Gao JQ. 2013. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. Int J Pharm. 444:1–9.
   PubMed Web of Science ®Google Scholar
• Majzoub RN, Chan CL, Ewert KK, Silva BF, Liang KS, Jacovetty EL, et al. 2014. Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging. Biomaterials. 35:4996–5005.
   PubMed Web of Science ®Google Scholar
• Majzoub RN, Ewert KK, Safinya CR. 2016. Cationic liposome–nucleic acid nanoparticle assemblies with applications in gene delivery and gene silencing. Phil Trans R Soc A. 374:20150129.
   Web of Science ®Google Scholar
• Mali S. 2013. Delivery systems for gene therapy. Indian J Hum Genet. 19:3.
   PubMedGoogle Scholar
• Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. 2003. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res. 63:3154–3161.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. 2005. Epidermal growth factor receptor–targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65:11631–11638.
   PubMed Web of Science ®Google Scholar
• Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. 2012. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet Oncol. 13:1234–1241.
   PubMed Web of Science ®Google Scholar
• Martins S, Sarmento B, Ferreira DC, Souto EB. 2007. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomed. 2:595.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. 1997. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev. 24:235–242.
   Web of Science ®Google Scholar
• Maruyama K. 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 63:161–169.
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G. 2002. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 277:27135–27143.
   PubMed Web of Science ®Google Scholar
• Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. 1996. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 37:1003–1008.
   PubMed Web of Science ®Google Scholar
• Medina OP, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, et al. 2011. Liposomal tumor targeting in drug delivery utilizing MMP-2-and MMP-9-binding ligands. J Drug Deliv. 2011:160515.
   PubMedGoogle Scholar
• Mendonça LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simões S. 2009. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem. 21:157–168.
   Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. 2012. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 13:105–119.
   PubMed Web of Science ®Google Scholar
• Mo R, Jiang T, Gu Z. 2014. Recent progress in multidrug delivery to cancer cells by liposomes. Nanomedicine (Lond). 9:1117–1120.
   PubMed Web of Science ®Google Scholar
• Moghimi HR, Saffari M, Dass CR. 2016. Barriers to liposomal gene delivery: from application site to the target. Iranian Journal of Pharmaceutical Research. 15:3–17.
   PubMed Web of Science ®Google Scholar
• Mourelatos Z. 2008. Small RNAs: the seeds of silence. Nature. 455:44–45.
   PubMed Web of Science ®Google Scholar
• Movahedi F, Hu RG, Becker DL, Xu C. 2015. Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics. Nanomedicine. 11:1575–1584.
   PubMed Web of Science ®Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. 2015. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 5:305.
   PubMed Web of Science ®Google Scholar
• Nelson AL. 2010. Antibody fragments: hope and hype. MAbs. 2:77–83.
   Google Scholar
• Nimjee SM, Rusconi CP, Sullenger BA. 2005. Aptamers: an emerging class of therapeutics. Annu Rev Med. 56:555–583.
   PubMed Web of Science ®Google Scholar
• Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen En Henegouwen PM. 2013. Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release. 172:607–617.
   PubMed Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP. 2011. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Mol Pharm. 9:176–186.
   PubMed Web of Science ®Google Scholar
• Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, et al. 2012. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 11:895–905.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. 2002. Anti-HER2 immunoliposomes enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 8:1172–1181.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M. 2003. Doxorubicin-loaded Fab′ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63:86–92.
   PubMed Web of Science ®Google Scholar
• Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 23:1243–1250.
   PubMed Web of Science ®Google Scholar
• Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. 2013. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 18:282–289.
   PubMed Web of Science ®Google Scholar
• Pisal DS, MP, Kosloski SV, Balu I. 2010. Delivery of therapeutic proteins. J Pharm Sci. 99:2557–2575.
   PubMed Web of Science ®Google Scholar
• Pore SK, Choudhary A, Rathore B, Ganguly A, Sujitha P, Kumar CG, et al. 2013. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials. 34:6804–6817.
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. 2009. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 26:523–580.
   PubMed Web of Science ®Google Scholar
• Rahman M, Kumar V, Beg S, Sharma G, Katare OP, Anwar F. 2016. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomed Biotechnol. 44:1597–1608.
   PubMed Web of Science ®Google Scholar
• Ramadas M, Paul W, Dileep KJ, Anitha Y, Sharma CP. 2000. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats. J Microencapsul. 17:405–411.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. 2015. Non viral vectors in gene therapy – an overview. J Clin Diagn Res. 9:GE01–GE06.
   PubMed Web of Science ®Google Scholar
• Ravar F, Saadat E, Gholami M, Dehghankelishadi P, Mahdavi M, Azami S, Dorkoosh FA. 2016. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. J Control Release. 229:10–22.
   PubMed Web of Science ®Google Scholar
• Reddy J, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP. 2002. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:1542–1550.
   PubMed Web of Science ®Google Scholar
• Reulen SW, Brusselaars WW, Langereis S, Mulder WJ, Breurken M, Merkx M. 2007. Protein-liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug Chem. 18:590–596.
   PubMed Web of Science ®Google Scholar
• Rhim T, Lee M. 2016. Targeted delivery of growth factors in ischemic stroke animal models. Exp Opin Drug Deliv. 13:709–723.
   PubMed Web of Science ®Google Scholar
• Rivest V, Phivilay A, Julien C, Bélanger S, Tremblay C, Emond V, Calon F. 2007. Novel liposomal formulation for targeted gene delivery. Pharm Res. 24:981–990.
   PubMed Web of Science ®Google Scholar
• Safra T. 2003. Cardiac safety of liposomal anthracyclines. The Oncologist. 8:17–24.
   PubMed Web of Science ®Google Scholar
• Sapra P, Moase EH, Ma J, Allen TM. 2004. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res. 10:1100–1111.
   PubMed Web of Science ®Google Scholar
• Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. 2008. Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 26:431–442.
   PubMed Web of Science ®Google Scholar
• Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H. 2015. Immunoliposomes for targeted delivery of an antifibrotic drug. Mol Pharm. 12:3146–3157.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. 2015. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 6:286.
   PubMed Web of Science ®Google Scholar
• Shim MS, Kwon YJ. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277:4814–4827.
   PubMed Web of Science ®Google Scholar
• Simoes S, Slepushkin V, Gaspar R, de Lima MC, Düzgüneş N. 1998. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther. 5:955–964.
   PubMed Web of Science ®Google Scholar
• Simoes S, Slepushkin V, Pires P, Gaspar R, de Lima MP, Düzgüneş N. 1999. Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides. Gene Ther. 6:1798–1807.
   PubMed Web of Science ®Google Scholar
• Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, Odunsi K, Demmy TL, et al. 2009. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol. 132:71–82.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW. 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 86:215–223.
   PubMed Web of Science ®Google Scholar
• Skandrani N, Barras A, Legrand D, Gharbi T, Boulahdour H, Boukherroub R. 2014. Lipid nanocapsules functionalized with polyethyleneimine for plasmid DNA and drug co-delivery and cell imaging. Nanoscale. 6:7379–7390.
   PubMed Web of Science ®Google Scholar
• Song X, Ren Y, Zhang J, Wang G, Han X, Zheng W, Zhen L. 2015. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes. Oncol Rep. 34:1953–1960.
   PubMed Web of Science ®Google Scholar
• Spuch C, Navarro C. 2011. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J Drug Deliv. 2011:469679.
   PubMedGoogle Scholar
• Steeland S, Vandenbroucke RE, Libert C. 2016. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 21:1076–1113.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Imai Y, Ueda K, Tsuruo T. 2003. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2:105–112.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, et al. 2008. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome. Int J Pharm. 346:143–150.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. 2003. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release. 86:235–242.
   PubMed Web of Science ®Google Scholar
• Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. 2002. Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats. Int J Cancer. 97:115–120.
   PubMed Web of Science ®Google Scholar
• Tian W, Ying X, Du J, Guo J, Men Y, Zhang Y, Li RJ, et al. 2010. Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur J Pharm Sci. 41:232–243.
   PubMed Web of Science ®Google Scholar
• Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. 2012. Drug delivery systems: an updated review. Int J Pharm Investig. 2:2.
   PubMedGoogle Scholar
• Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GG. 2003. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA. 100:1972–1977.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Martin SM, Ma Y, Zamboni W, O’Donnell RT. 2010. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non–Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res 16:2760–2768.,
   PubMed Web of Science ®Google Scholar
• Vaidya B, Agrawal G, Vyas SP. 2011. Platelets directed liposomes for the delivery of streptokinase: development and characterization. Eur J Pharm Sci. 44:589–594.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, et al. 2012. Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release. 159:281–289.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV. 2013. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 65:1284–1298.
   PubMed Web of Science ®Google Scholar
• Voinea M, Simionescu M. 2002. Designing of ‘intelligent’ liposomes for efficient delivery of drugs. J Cell Mol Med. 6:465–474.
   PubMed Web of Science ®Google Scholar
• Wang F, Chen L, Zhang R, Chen Z, Zhu L. 2014. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J Control Release. 196:222–233.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao P, Su W, Wang S, Liao Z, Niu R, Chang J. 2010. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials. 31:8741–8748.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou J, Qiu L, Wang X, Chen L, Liu T, Di W. 2014. Cisplatin–alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials. 35:4297–4309.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H, et al. 2012. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials. 33:8451–8460.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. 2009. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 8:129–138.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu Q, Lee RJ. 2006. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm. 316:148–153.
   PubMed Web of Science ®Google Scholar
• Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ. 2007. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 10:350–357.
   PubMed Web of Science ®Google Scholar
• Xiong S, Yu B, Wu J, Li H, Lee RJ. 2011. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed Pharmacother. 65:2–8.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM. 2002. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes 1 This work was supported in part by National Cancer Institute Grant R01 CA45158 (to EC), National Cancer Institute Small Business Technology Transfer Phase I Grant R41 CA80449 (to EC), and a grant from SynerGene Therapeutics, Inc. 1. Mol Cancer Ther. 1:337–346.
   PubMed Web of Science ®Google Scholar
• Xu X, Costa A, Burgess DJ. 2012. Protein encapsulation in unilamellar liposomes: high encapsulation efficiency and a novel technique to assess lipid-protein interaction. Pharm Res. 29:1919–1931.
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD. 2007. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 24:2402–2411.
   PubMed Web of Science ®Google Scholar
• Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, et al. 2014. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics. 4:1096–1111.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, et al. 2010. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 141:183–192.
   PubMed Web of Science ®Google Scholar
• Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, Dewa T, Nango M, Oku N. 2012. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J Control Release. 160:177–181.
   PubMed Web of Science ®Google Scholar
• Yu B, Mao Y, Bai L, Herman SEM, Wang X, Ramanunni A, et al. 2013. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood. 121:136–147.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man C, Tagalakis AD, Manunta MD, Hart SL, Khaw PT. 2016. Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis. Scientific Rep. 6:21881.
   PubMed Web of Science ®Google Scholar
• Zalba S, Contreras AM, Haeri A, Ten Hagen TL, Navarro I, Koning G, Garrido MJ. 2015. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release. 210:26–38.
   PubMed Web of Science ®Google Scholar
• Zamboni WC. 2005. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res. 11:8230–8234.
   PubMed Web of Science ®Google Scholar
• Zhang CX, Zhao WY, Liu L, Ju RJ, Mu LM, Zhao Y, et al. 2015. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Oncotarget. 6:32681.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R, Jiang Y, He F. 2008. Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett. 269:26–36.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, et al. 2012. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 33:565–582.
   PubMed Web of Science ®Google Scholar
• Zhang X, Koh CG, Yu B, Liu S, Piao L, Marcucci G, Lee RJ, Lee LJ. 2009. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharmaceu Res. 26:1516–1524.
   Web of Science ®Google Scholar
• Zhang Y, Satterlee A, Huang L. 2012. In vivo gene delivery by nonviral nectors: overcoming hurdles. Mol Ther. 20:1298–1304.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yao J. 2012. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity. AAPS PharmSciTech. 13:802–810.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. 2009. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target. 17:10–18.
   PubMed Web of Science ®Google Scholar